Švédsko - švédština - Läkemedelsverket (Medical Products Agency)

meda ab - tramadolhydroklorid - depotkapsel, hård - 50 mg - sockersfärer hjälpämne; tramadolhydroklorid 50 mg aktiv substans; propylenglykol hjälpämne - tramadol

Švédsko - švédština - Läkemedelsverket (Medical Products Agency)

2care4 aps - tramadolhydroklorid - depotkapsel, hård - 50 mg - propylenglykol hjälpämne; tramadolhydroklorid 50 mg aktiv substans; sockersfärer hjälpämne

Švédsko - švédština - Läkemedelsverket (Medical Products Agency)

2care4 aps - tramadolhydroklorid - depotkapsel, hård - 100 mg - tramadolhydroklorid 100 mg aktiv substans; propylenglykol hjälpämne; sockersfärer hjälpämne

Švédsko - švédština - Läkemedelsverket (Medical Products Agency)

orifarm ab - tramadolhydroklorid - depotkapsel, hård - 50 mg - propylenglykol hjälpämne; tramadolhydroklorid 50 mg aktiv substans; sockersfärer hjälpämne

Švédsko - švédština - Läkemedelsverket (Medical Products Agency)

2care4 aps - tramadolhydroklorid - depotkapsel, hård - 50 mg - sockersfärer hjälpämne; propylenglykol hjälpämne; tramadolhydroklorid 50 mg aktiv substans

Evropská unie - švédština - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Evropská unie - švédština - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - obesity; overweight - antiobesity preparat, exkl. kost produkter - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Evropská unie - švédština - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - diabetes mellitus - läkemedel som används vid diabetes - behandling av vuxna med otillräckligt kontrollerad typ 2-diabetes som ett komplement till diet och motion:som monoterapi när metformin är olämpliga på grund av intolerans eller kontraindikationer, i tillägg till andra läkemedel för behandling av diabetes. för att studera resultaten med avseende kombinationer av effekter på glykemisk kontroll och kardiovaskulära händelser, och de populationer som studeras, se avsnitt 4. 4, 4. 5 och 5.

Evropská unie - švédština - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Evropská unie - švédština - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multipelt myelom - antineoplastiska medel - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.